Floatz logo

Eloxatin

Endocrine Gland Neoplasms

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Endocrine Gland Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Xiaoxiang Chen
Phase 2BB
Trabectedin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
DEXAMETHASONE
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
Niraparib
Xiaoxiang Chen
Phase 2CCC
(+)-VINCRISTINE
Xiaoxiang Chen
Phase 2CCC

View all 12 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →